Company intelligence / Profile preview

Tianjin Jinster Vaccine

Tianjin, Tianjin, China

Ownership: Private
Development stage: Other

Overview

Tianjin Jinster Vaccine is a Chinese biotechnology company specializing in the research, development, and manufacturing of innovative vaccine products. The company focuses on high-value vaccine candidates, including recombinant human papillomavirus (HPV) vaccines and COVID-19 vaccines. Leveraging its recombinant protein technology platform, Jinster aims to address significant public health challenges through the production of safe and effective immunotherapies. The company is part of the growing biotech cluster in Tianjin, contributing to China's domestic vaccine self-sufficiency and global health initiatives.

Therapeutic areas: Infectious DiseasesOncology
Modalities: VaccineBiologicRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Tianjin Jinster Vaccine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin Jinster Vaccine.

Explore the full profile